Evidence map›Paper›PMID 41788291›Full record

ArticleACS materials letters2026

Protein-Linker Co-engineering for Broad-Spectrum Antiviral Development against Enveloped Viruses.

Lixia Wei, Colleen N Loynachan, Gregory Mathez, Yong Zhu, Suiyang Liao, Arnaud Charles-Antoine Zwygart, Laure Menin, Caroline Tapparel, Valeria Cagno, Francesco Stellacci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS materials letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lixia WeiInstitute of Materials Science and Engineering, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.
Colleen N LoynachanInstitute of Materials Science and Engineering, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID https://orcid.org/0000-0001-5617-4091
Gregory MathezInstitute of Microbiology, Lausanne University Hospital, University of Lausanne, Lausanne 1011, Switzerland.ORCID https://orcid.org/0000-0002-4453-7649
Yong ZhuInstitute of Materials Science and Engineering, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID https://orcid.org/0000-0001-7213-7864
Suiyang LiaoInstitute of Materials Science and Engineering, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID https://orcid.org/0000-0003-0705-9112
Arnaud Charles-Antoine ZwygartDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva 1206, Switzerland.
Laure MeninInstitute of Chemical Sciences and Engineering, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.
Caroline TapparelDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva 1206, Switzerland.
Valeria CagnoInstitute of Microbiology, Lausanne University Hospital, University of Lausanne, Lausanne 1011, Switzerland.ORCID https://orcid.org/0000-0002-5597-334X
Francesco StellacciInstitute of Materials Science and Engineering, École polytechnique fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID https://orcid.org/0000-0003-4635-6080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging and re-emerging viruses with pandemic potential pose a continuous global health threat. Broad-spectrum antivirals, if available, could serve as a critical first line of defense. Here, we present a general and simple strategy to chemically functionalize natural proteins into broad-spectrum, nontoxic antivirals. Through a one-step conjugation, proteins are modified with alkyl ligands terminated by secondary amines. These functionalized proteins exhibit potent inhibitory activity against enveloped viruses HSV-2, Influenza A H1N1, and SARS-CoV-2, with half-effective concentrations (EC

Identifiers

PMID41788291
PMCPMC12958346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.